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a b s t r a c t
There is accumulating and convincing evidence indicating a role for glutamate in the
pathogenesis of the human demyelinating disease multiple sclerosis (MS). Studies in experi-
mental autoimmune encephalomyelitis (EAE), the animal model of MS, demonstrate that
pharmacological inhibition of specific glutamate receptors suppresses neurological symp-
toms and prevents blood–brain barrier (BBB) breakdown. The mechanisms through which
glutamate influences BBB function during EAE remain unclear. Glutamate triggers the pro-
duction of nitric oxide and superoxide, which can lead to the formation of peroxynitrite
(ONOO). Recent studies have implicated ONOO in the loss of neurovascular integrity during
EAE. We propose that glutamate contributes to BBB breakdown via the actions of ONOO. The
present investigation examined glutamate-induced ONOO formation in the b.End3 brain-
derived endothelial cell line. b.End3 cells were incubated with a concentration range of
glutamate and ONOO production was assessed over time. Results showed a concentration-
and time-dependent increase in ONOO levels in glutamate-treated cells that were sup-
pressed by selective and non-selective inhibitors of ONOO-mediated reactions. Specific
activation of b.End3-associated NMDA receptors also resulted in a concentration-dependent
increase in ONOO production. The ability of b.End3 cells to respond to the presence of
glutamate was confirmed through the detection of NMDA receptor immnuoreactivity in cell
extracts. In addition, the use of the NMDA receptor antagonists MK-801 and memantine
reduced glutamate-mediated ONOO generation from b.End3 cells. The data reinforce the
important relationship between glutamate and the NMDA receptor, positioned at neurovas-
cular sites, which maybe of particular relevance to the pathogenesis ofdemyelinating disease.
# 2006 Elsevier Inc.
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Multiple sclerosis (MS) is a human neurodegenerative disorder
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Open access under CC BY license.excitatory amino acid glutamate has an important role in the
pathogenesis of MS [1–3]. Glutamate concentrations are
increased in cerebrospinal fluid from MS patients and the
levels correlate with the severity of disease [4,5]. Alterations inperimental Pathology, The William Harvey Research Institute, St.
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identified in MS patients and changes to the balance of
glutamate in the central nervous system (CNS) have been
associated with local tissue damage [6–8]. Related work in the
animal model of MS, experimental autoimmune encephalo-
myelitis (EAE), strongly implicates glutamate in disease
development [9–11]. In particular, N-methyl-D-aspartate
(NMDA) and a-amino-3-hydroxy-5-methyl-4-isoxazolepropio-
nic acid (AMPA) receptor antagonists have been shown to
suppress EAE, and inhibition of glutamate transmission also
reduces disease severity [12–16].
There may be many pathways through which glutamate
mediates deleterious effects in MS and EAE but the ability of
glutamate to induce CNS cell death has gained particular
attention [17]. Indeed, glutamate-induced excitotoxicity is
thought to contribute to oligodendrocyte and axonal loss in MS
and EAE and the amino acid also exerts toxic effects on
neurons [8,14,18–21]. Several studies have proposed glutamate
involvement in the pathogenesis of MS and EAE through
altering blood–brain barrier (BBB) integrity. The BBB assists in
the maintenance of homeostasis in the CNS [22] and abnormal
neuroendothelial function during MS and EAE allows excess
movement of fluid and cells into brain and spinal tissues
[23,24]. Several studies have shown that glutamate directly
modulates neurovascular integrity [25–27] and administration
of glutamate receptor antagonists restricts BBB breakdown
during EAE [12,13].
The mechanisms through which glutamate modifies
neurovascular integrity are unclear but have been shown to
involve the vasoactive molecules nitric oxide (NO) and
superoxide (O2
) that can combine to form damaging levels
of peroxynitrite (ONOO) [25,28–30]. Indeed, glutamate is
known to stimulate the production of NO and O2
 and has the
capacity to generate ONOO in the CNS [31]. Therefore,
glutamate has the potential to mediate BBB breakdown in
MS and EAE via the actions of ONOO.
The current study employed the brain endothelial cell line,
b.End3, to investigate the relationship between glutamate-
mediated NMDA receptor activation and ONOO production in
neuroendothelial breakdown. The work confirms b.End3 cells
generate ONOO following exposure to glutamate. In parti-
cular, the investigation suggests glutamate-mediated ONOO
production by b.End3 cells occurs through NMDA receptor
activation and NO production via up-regulation of specific NO
synthase activity.2. Materials and methods
2.1. Chemicals and antibodies
NG-Nitro-L-arginine methyl ester (L-NAME),NG-monomethyl-L-
arginine (L-NMMA), L-N5-(1-iminoethyl)ornithine (L-NIO),
N-acetyl-L-cysteine (N-AC) and N-(3-(aminomethyl)benzyl)
acetamidine (1400W) were obtained from Alexis Corporation,
Nottingham, UK. MK-801 (dizocilpine maleate, (5R,10S)-(+)-
5-methyl-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-10-
imine maleate), memantine (3,5-dimethyl-tricyclo [3.3.1.13,7]
decan-1-amine hydrochloride), 2,3-dioxo-6-nitro-1,2,3,4-tet-
rahydrobenzo-[f]quinoxaline-7-sulphonamide (NBQX), (RS)-a-cyclopropyl-4-phosphonophenylglycine (CPPG) and N-phe-
nyl-7-(hydroxyimino) cyclopropa[b] chromen-1a-carboxa-
mide (PHCC) were purchased from Tocris Cookson Ltd,
Bristol, UK. Anti-mouse NMDAR1 and NMDAR2A/B polyclonal
antibodies were purchased from Chemicon International,
Hants, UK. Enhanced chemiluminescence (ECL) reagent was
obtained from Amersham Biosciences, Bucks, UK. Peroxidase
conjugated goat anti-rabbit antibody and uric acid (UA) were
purchased from Calbiochem, Nottingham, UK.
2.2. Culture of b.End3 cells
The SV129 mouse brain endothelial cell line b.End3 (European
Collection of Animal Cell Cultures, Wiltshire, UK), established
using the Polyoma virus middle T-antigen [32], was main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 2 mM L-glutamate, 5 mM mercaptoetha-
nol, 1% non-essential amino acids, 10% fetal bovine serum,
1 mM sodium pyruvate, 50 U/ml penicillin and 50 mg/ml
streptomycin (Invitrogen Ltd, Paisley, Scotland, UK).
2.3. Cell treatment
b.End3 cells were cultured in 96 well plates at a density of
5  104 cells/ml. Confluent cell preparations were incubated
with a range of glutamate concentrations for 1, 4 and 24 h to
determine ONOO and NO production and assess cell viability.
In addition, b.End3 cells, at an original density of 2.5 
105 cells/ml, were cultured to confluence in 24 well plates and
exposed to glutamate in the presence and absence of UA,
selective NOS inhibitors and glutamate receptor antagonists.
The generation of ONOO by b.End3 cells was then assessed at
pre-determined time points.
2.4. Cell viability
The mitochondrial-dependent reduction of 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium (MTT) to
formazan was used as an indicator of cell viability. Cells
in 96-well plates were exposed to glutamate concentrations
from 0.001 mM to 20 mM for 1, 4 or 24 h followed by the
addition of MTT, at 0.2 mg/ml, to the cultures. After 1 h
incubation at 37 8C, supernatants were removed and the
cells lysed by the addition of 100 ml aliquots of dimethyl
sulphoxide to each well. The reduction of MTT to formazan
within cells was measured using a Spectramax 250-micro-
plate reader (Biotek EL310) at 550 nm absorbance. Results
are expressed as percentage (%) viability compared to
untreated controls.
2.5. Measurement of NO production
The generation of NO was assessed by measuring nitrite, the
co-principle, stable end-product of NO metabolism, in cell
supernatants. The assay, developed from a previous method
[33] quantified nitrite by adding an equal volume of Griess
reagent to each cell supernatant and, after incubation at room
temperature for 10 min, the absorbance of each sample was
read at 550 nm using a microplate reader (Spectramax 250,
Biotek EL310). The nitrite level in samples was determined by
Fig. 1 – Viability of b.End3 cells exposed to glutamate.
b.End3 cells were treated with varying concentrations of
glutamate for 1, 4, and 24 h. Cell viability wasmeasured by
the mitochondrial-dependent reduction of MTT to
formazan. Results are presented as % viability compared
to untreated cultures. *p < 0.05 and **p < 0.01 compared to
control group by one-way ANOVA with post hoc Dunnet’s
test.
b i o c h em i c a l p h a rma c o l o g y 7 3 ( 2 0 0 7 ) 2 2 8 – 2 3 6230reference to a series of sodium nitrite standards prepared in
culture medium. Results are presented asmM nitrite/100 ml cell
supernatant.
2.6. Measurement of ONOOS formation
The formation of ONOO was determined by measuring the
ONOO-dependent oxidation of dihydrorhodamine (DHR) 123
to rhodamine 123 by b.End3 cells. Following glutamate
treatment cell preparations were rinsed with phosphate
buffered saline and incubated with 5 mM DHR 123 for 1 h at
37 8C. The fluorescence of rhodamine 123 was measured at
excitation 485 nm, emission 530 nm using a fluorescent plate
reader (Cytofluor II, Perseptive Biosystems). Results are
expressed as % oxidation compared to untreated control
cultures.
2.7. Western blot analysis of b.End3 cell preparations
Whole cell lysates were prepared from untreated b.End3
cells using Laemmli’s buffer. Each sample, containing 30 mg
protein, was separated on 10% SDS-PAGE gels and trans-
ferred to nitrocellulose membranes using semi-dry transfer
techniques. Membranes were blocked with 10% milk protein
and incubated overnight at 4 8C with 1:250 dilution of
rabbit anti-mouse NMDAR1 or NMDAR2A/B polyclonal anti-
body. The membranes were washed, incubated for 1 h in
1:2000 dilution of peroxidase conjugated goat anti-rabbit
antibody and the protein bands visualized using ECL
reagent.
2.8. Statistical analysis
All values are expressed as the mean  S.E.M. of n observa-
tions, where n > 6 from at least three independent experi-
ments. Data sets were analysed by one-way analysis of
variance (ANOVA) followed by post hoc Dunnett’s test. In all
tests, p < 0.05 was considered significant.3. Results
3.1. Effects of glutamate on b.End3 cell viability
Normal physiological levels of glutamate in CNS cells are
less than 3 mM but, during disease and injury, the interstitial
fluid concentration can rise dramatically [34]. The precise
concentrations of glutamate in the CNS during MS and EAE
are unknown but elevations above normal levels have been
reported [5,6,35]. Glutamate, at millimolar concentrations, is
known to exert toxic effects on CNS-derived preparations,
including cells isolated from neuroendothelial tissues
[27,36]. Therefore, initial experiments were undertaken in
b.End3 cells to establish a glutamate concentration that did
not affect cell viability but induced ONOO release. The cells
were incubated in the presence of glutamate, at concentra-
tions from 1 mM to 100 mM, for 1, 4 and 24 h and cell viability
was determined by assessing mitochondrial respiration.
Glutamate levels between 1 mM and 10 mM did not
affect viability in b.End3 cells over a 24 h period (Fig. 1). Incontrast, concentrations of glutamate between 30 mM and
100 mM were associated with significant reductions in cell
viability.
Glutamate may influence cell survival by altering the pH of
the culture conditions. The pH of the media was determined
after the addition of glutamate and was closely maintained at
pH 7.4 up to a concentration of 20 mM (data not shown).
Therefore, subsequent dose response experiments, to estab-
lish a level of glutamate which influenced NO and ONOO
production, were conducted using a maximum glutamate
concentration of 20 mM.
3.2. Glutamate-induced NO and ONOOS production by
b.End3 cells
The production of NO, measured as nitrite, and ONOO,
quantified by DHR oxidation, in b.End3 preparations, after
exposure to increasing concentrations of glutamate, are
detailed in Fig. 2A and B. Nitrite levels remained unchanged
in cells after incubation, for 1–24 h, with glutamate at
concentrations from 0.001 mM to 1 mM (Fig. 2A). Treatment
of b.End3 cells with 5 mM to 20 mM glutamate, caused a
significant increase in nitrite levels at 24 h. Moreover, 20 mM
glutamate induced a significant and sustained elevation in
nitrite concentrations from preparations incubated for 1 h.
The production of ONOO revealed a similar profile to nitrite
release after treatment of b.End3 cells with glutamate (Fig. 2B).
Incubation of cells with 5 mM to 20 mM glutamate elicited a
significant dose-dependent increase in ONOO synthesis.
Furthermore, 20 mM glutamate raised DHR oxidation levels
4 h post-incubation.
Data from the preceding experiments confirmed that
exposure of b.End3 cells to 10 mM glutamate induced a
significant, reproducible and non-cytotoxic increase in
ONOO production. Therefore, the supra-physiological con-
centration of 10 mM glutamate was used to characterise
reactive nitrogen species production and NMDA receptor
activation by b.End3 cells.
Fig. 2 – NO and ONOOS production by b.End3 cells exposed
to glutamate. b.End3 cells were treated with varying
concentrations of glutamate for 1, 4, and 24 h. (A) NO
production was measured as the nitrite content (mM) of
cell culture supernatants using the Griess assay and (B)
ONOOS production was determined by measuring the
oxidation of dihydrorhodamine (DHR) to produce the
fluorescent rhodamine. Results are presented as %
increase in DHR oxidation compared to untreated cultures.
*p < 0.05 and **p < 0.01 compared to control group by
one-way ANOVA with post hoc Dunnet’s test.
Fig. 3 – The effect of free radical inactivation, the blockade
of NO production and anti-oxidants on glutamate-induced
ONOOS formation by b.End3 cells. Cells were exposed to
10 mM glutamate for 24 h in the presence of increasing
concentrations of: (A) UA, (B) L-NMMA and (C) N-AC.
ONOOS production was measured by the oxidation of
dihydrorhodamine (DHR) to produce the fluorescent
rhodamine. Results are presented as % increase in DHR
oxidation compared to untreated cells. *p < 0.05 and
**p < 0.01 compared to control group by one-way ANOVA
with post hoc Dunnet’s test.
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The decomposition of ONOO, formed as a consequence of NO
and O2
 interaction, generates highly reactive intermediates
that can be inactivated by UA, a selective scavenger of ONOO-
dependent radicals [28,29]. DHR oxidation in unstimulated
b.End3 cells was significantly reduced by the addition of
increasing UA concentrations (p < 0.01) (Fig. 3A). Similarly,
each dose of UA significantly inhibited DHR oxidation in
glutamate-stimulated cultures (p < 0.01). The inhibitory
effects of UA on basal and induced DHR oxidation in b.End3
cells strongly indicate that the major oxidising species present
was ONOO. The competitive, irreversible, pan-NOS inhibitor
L-NMMA significantly reduced basal and glutamate-induced
DHR oxidation in b.End3 cells (p < 0.01) (Fig. 3B). The addition
of N-AC, a precursor of the anti-oxidant glutathione, to
unstimulated and glutamate-exposed cultures generated a
modest and significant inhibition of DHR oxidation (p < 0.05)
(Fig. 3C).
3.4. Receptor types mediating glutamate-stimulated
ONOOS production
Initiation of a cellular response to glutamate requires the
activation of the ionotropic, NMDA and AMPA/kainatereceptors, or metabotropic receptors [37]. Several antago-
nists were employed to determine the receptor type involved
in glutamate-induced ONOO production from b.End3
cells. The addition of increasing concentrations of PHCC, a
potent and selective group I metabotropic glutamate
receptor antagonist, to unstimulated b.End3 cells elicited a
Fig. 4 – The effect of glutamate receptor antagonists on glutamate-induced ONOOS production by b.End3 cells. Cells were
exposed to 10 mM glutamate for 24 h in the presence of increasing concentrations of: (A) PHCC, (B) CPPG, (C) NBQX, (D) MK-
801 and (E) Memantine. ONOOS production was measured by the oxidation of dihydrorhodamine (DHR) to produce the
fluorescent rhodamine. Results are presented as % increase in DHR oxidation compared to untreated cultures. *p < 0.05,
**p < 0.01 and ***p < 0.001 compared to control group by one-way ANOVA with post hoc Dunnet’s test.
b i o c h em i c a l p h a rma c o l o g y 7 3 ( 2 0 0 7 ) 2 2 8 – 2 3 6232detectable, but not significant, increase in DHR oxidation
(Fig. 4A). The compound did not alter DHR oxidation
in cultures exposed to glutamate. CPPG, a group II/III
metabotropic receptor antagonist, had no effect on DHR
oxidation in unstimulated or glutamate-stimulated b.End3
cells (Fig. 4B). Similarly, NBQX, a competitive AMPA/kainate
receptor antagonist, did not alter basal or glutamate-
induced responses in the cultures (Fig. 4C). In contrast,
the selective, non-competitive NMDA ionotropic glutamate
receptor antagonist, MK-801 elicited a modest inhibition of
DHR oxidation in unstimulated b.End3 cells and significant
changes in glutamate-rich cells (Fig. 4D), ( p < 0.05–0.01).
High concentrations of memantine, a relatively low potency,
uncompetitive NMDA receptor antagonist that targets
the channel pore, significantly suppressed DHR oxidation
in unstimulated cultures ( p < 0.05) (Fig. 4E). In particular,each dose of the drug added to glutamate-stimulated
cultures significantly inhibited DHR oxidation ( p < 0.05–
0.001).
3.5. Glutamate receptor expression on b.End3 cells
Collectively, the results provide compelling evidence that
glutamate-stimulated ONOO production by b.End3 cells is
mediated through NMDA receptor involvement. Further
evidence indicating the presence of the receptor on b.End3
cells is provided by the dose-dependent production of ONOO
following exposure of the cultures to the specific receptor
ligand NMDA (Fig. 5). The location of NMDA receptors on
b.End3 cells was also confirmed by incubation of separated
protein extracts, from individual cultures, with specific and
selective antibodies against the NMDA R1 and NMDA R2A/B
Fig. 5 – The effect of NMDA on ONOOS production by b.End3
cells. Cells were incubated with increasing concentrations
of NMDA for 24 h. ONOOS production was determined by
measuring the oxidation of dihydrorhodamine (DHR) to
produce the fluorescent rhodamine. Results are presented
as % increase in DHR oxidation compared to untreated
controls. **p < 0.01 compared to control group by one-way
ANOVA with post hoc Dunnet’s test.
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firmed the NMDA R1 and NMDA R2A/B receptor to have
molecular weights of approximately 125 kDa and 180 kDa,
respectively [38,39] which corresponds with the values
recorded in the current study.
3.6. NOS isoforms involved in the b.End3 cell response to
glutamate
The involvement of NOS isoforms in glutamate-stimulated
ONOO production by b.End3 cells was examined using
specific inhibitors at concentrations previously shown to
alter NOS function in vitro [40,41]. DHR oxidation was
significantly inhibited in unstimulated and glutamate-
exposed cultures at all concentrations of the pan-NOSFig. 6 – The presence of NMDA Receptor 1 (A) and NMDA
receptor 2A/B (B) in protein extracts from b.End3 cells
subjected to Western blotting techniques. Each lane
represents whole cell extracts from three individual,
untreated b.End3 cultures.
Fig. 7 – The effect of NOS inhibition on glutamate-induced
ONOOS production by b.End3 cells. Cells were exposed to
10 mM glutamate for 24 h in the presence of increasing
concentrations of: (A) L-NAME, (B) NIO and (C) 1400W.
ONOOS production was determined by measuring the
oxidation of dihydrorhodamine (DHR) to produce the
fluorescent rhodamine. Results are presented as %
increase in DHR oxidation compared to untreated cells.
*p < 0.05, ***p < 0.001 compared to control group by one-
way ANOVA with post hoc Dunnet’s test.inhibitor L-NAME (Fig. 7A) ( p < 0.001). The endothelial
(e) NOS inhibitor L-NIO also significantly suppressed
DHR oxidation in b.End3 cells in the presence and
absence of glutamate (Fig. 7B) ( p < 0.05 or 0.001) but the
inducible (i) NOS inhibitor, 1400W [42] (Fig. 7C), was without
effect.
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The current study has demonstrated that the brain endothelial
cell line, b.End3, releases ONOO and NO in the presence of a
pre-determined, supra-physiological concentration of gluta-
mate. In particular, ONOO generation, as quantified by DHR
production, was significantly attenuated by the selective
scavenger UA, the pan-NOS inhibitors L-NAME and L-NMMA,
the anti-oxidant glutathione precursor N-AC and the eNOS
inhibitor L-NIO. Moreover, the investigation strongly suggests
the release of ONOO by b.End3 cells, in response to
glutamate, is mediated via the NMDA receptor and not
through AMPA/kainate receptor involvement.
BBB disruption is a cardinal sign of new and active lesions
in MS but the pathways leading to neuroendothelial break-
down are not understood despite the identification of several
candidate mediators [23,43–45]. Emerging evidence strongly
implicates a relationship between glutamate, NMDA activa-
tion and reactive nitrogen species in the pathogenesis of MS
and the related model, EAE [1,9,46]. In particular, the
identified mediators have been suggested as important
participants in causing loss of BBB integrity during MS and
EAE [12,13,29,47].
The b.End3 cell line used in the present study has been
shown in previous investigations to retain many of the
characteristics of primary endothelial cells. For example, the
cultures express endothelial-specific proteins including
PECAM-1, endoglin, MECA-32 and Flk-1 and respond to
inflammatory cytokines with the up-regulation of adhesion
molecules such as ICAM-1, VCAM-1 and E-selectin and the
S100 chemotactic protein CP-10 [48–54]. Furthermore, trans-
formed cells, in contrast to non-immortalized cultures,
display cytoplasmic localisation of the tight junction-asso-
ciated proteins, occludin and zona occludin-1 and express
iNOS and eNOS [55,56]. The results from our work further
characterise the cell line by demonstrating the basal release
of ONOO and NO and, in particular, the significant produc-
tion of both species in response to the excitotoxic mediator
glutamate.
In order to investigate the mechanisms through which
glutamate induces ONOO and NO production from b.End3
cells a variety of compounds that interfere with the possible
pathways to generation of the free radicals were employed.
Moreover, a selection of the drugs used have relieved the
neurological deficits and prevented BBB breakdown in models
of EAE. For example, the selective ONOO scavenger UA has
been successfully used to inhibit EAE and limit permeability
changes in endothelial cells in vitro [28,29,47,57]. The compe-
titive NOS inhibitor L-NMMA has been employed in EAE, with
variable efficacy, and treatment with the O2
 scavenger N-AC
suppressed acute EAE through biasing immune response
mechanisms [58–61]. In the present investigation the addition
of UA, L-NMMA and N-AC to b.End3 cultures effectively
reduced the spontaneous and glutamate-induced release of
ONOO and therefore indicates a common target for the action
of the compounds in EAE.
The identity of the mechanisms controlling ONOO
production by b.End3 cells becomes clearer with the use of
NMDA and AMPA/kainate receptor antagonists. We and others
have confirmed the inhibitory influence of the NMDA receptorantagonists MK-801 and memantine on the neurological
course and BBB disruption observed in EAE [12,13]. Further-
more, the usefulness of the AMPA/kainate receptor blocker
NBQX has been shown in acute and chronic-relapsing models
of the disease [14,15,20]. Interestingly, the generation of
ONOO, by the endothelial cell line, was exclusively inhibited
by the NMDA receptor antagonists MK-801 and memantine.
Involvement of the NMDA receptor in ONOO formation was
further confirmed by the release of the molecule following
incubation of cultures with the specific agonist NMDA. Finally,
the presence of the receptor in association with b.End3 cells
was demonstrated by the constitutive expression of NMDA R1
and NMDA R2A/B receptors, as has been previously noted for
cerebral endothelial cells [62].
Results from the current study strongly indicating NMDA
receptor presence on b.End3 cells, via the use of ionotropic
and metabotropic receptor antagonists, are comparable to
previous observations made using human and immortalized
brain endothelial cells [27]. In particular, exposure of the
human-derived cultures to glutamate or NMDA reduced
endothelial barrier function that could be blocked using MK-
801 and N-AC. Therefore, the data clearly indicate the
presence of NMDA receptors in neuroendothelial prepara-
tions and involvement of the receptor in endothelial function.
Also, both studies add credence to the theory that the
monosodium derivative of glutamate may be toxic at
neurovascular sites and lead to a breakdown in normal BBB
function [63,64].
Glutamate-induced NMDA receptor activation leads to
removal of the magnesium channel block, calcium influx and
the up-regulation of various enzymes including NOS [9]. NOS
exists as several isoforms that are susceptible to inhibition by
specific and non-specific agents [65]. The preferential reduc-
tion of ONOO production by the selective eNOS inhibitor L-
NIO strongly suggests involvement of the isoform in
glutamate receptor-mediated events. Moreover, exposure
of cells to the specific iNOS inhibitor 1400W [66,67] was
without effect on ONOOproduction indicating no role for the
isoform in generation of the free radical. Therefore, gluta-
mate may act at the NMDA receptor site on brain endothelial
cells to enhance calcium influx thereby up-regulating eNOS,
to cause the formation of NO and the subsequent generation
of ONOO.
In conclusion, the study has shown the brain-derived cell
line b.End3 produces NO and ONOO in response to non-
cytotoxic concentrations of the amino acid glutamate. The
work also provides clear evidence that glutamate promotes
inflammatory mediator release by acting as an agonist for
b.End3-associated NMDA receptors. The results offer more
understanding of the important relationship between
glutamate and the NMDA receptor positioned at neurovas-
cular sites that may be of particular relevance in the
pathogenesis of demyelinating disease and other CNS-
related conditions.
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